The Effect of Potatoes on Markers of Cardiometabolic Health
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
University Park, Pennsylvania, United States, 16802
- Pennsylvania State University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Non-smoking
- BMI > 20 and <40 kg/m2
- Male or female
Exclusion Criteria:
- Diagnosed diabetes or fasting glucose >126 mg/dl
- Hypertension (systolic blood pressure >160mmHg or diastolic blood pressure >100mmHg)
- Prescribed anti-hypertensive, lipid lowering or glucose lowering drugs
- Established cardiovascular disease, stroke, diabetes, liver, kidney or autoimmune disease or inflammatory conditions
- Use of supplements (psyllium, fish oil, soy lecithin, phytoestrogens) and botanicals and not willing to cease for the duration of the study
- Pregnancy or lactation
- Weight loss of >=10% of body weight within the 6 months prior to enrolling in the study
- Smoking or use of any tobacco products
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Potato treatment
Participants will be provided with one potato-based side dish, equivalent to one medium sized potato, every day for 4 weeks for incorporation into their self-selected diet.
The potato-based side dish will be prepared at the Penn State Metabolic Kitchen.
The potato side dish will consist of commonly consumed potato-based sides in the U.S. and there will be limited inclusion of ingredients high in saturated fat, refined sugars or sodium.
French fries will not be provided.
The variety of potatoes will represent consumption patterns in the U.S. including white, russet, yellow and red potatoes.
|
Daily consumption of a potato-based side dish equivalent to one medium size potato for 4 weeks
|
|
Active Comparator: Refined grain treatment
Participants will be provided with a calorie-matched refined grain-based side dish every day for 4 weeks for incorporation into their self-selected diet.
The refined grain-based side dishes will be prepared at the Penn State Metabolic Kitchen and ingredients high in saturated fat, refined sugar or sodium will not be used.
These will be sides commonly eaten in the U.S. (e.g.
pasta made with white flour and white rice, white bread rolls).
During this treatment, participants will be told not to consume potatoes.
|
Daily consumption of an isocaloric refined grain-based side dish for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Fasting blood glucose
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Triglycerides
Time Frame: 4 weeks
|
4 weeks
|
|
Total cholesterol
Time Frame: 4 weeks
|
4 weeks
|
|
LDL cholesterol
Time Frame: 4 weeks
|
4 weeks
|
|
Homeostasis Model of Assessment of Insulin Resistance
Time Frame: 4 weeks
|
4 weeks
|
|
Peripheral blood pressure
Time Frame: 4 weeks
|
4 weeks
|
|
Central blood pressure
Time Frame: 4 weeks
|
4 weeks
|
|
Pulse Wave Velocity
Time Frame: 4 weeks
|
4 weeks
|
|
Augmentation index
Time Frame: 4 weeks
|
4 weeks
|
|
Diet quality measured by the Healthy Eating Index 2010
Time Frame: 4 weeks
|
4 weeks
|
|
Change in fecal short chain fatty acid levels
Time Frame: Week 0; Week 2 of treatment period 1; Week 4 of treatment period 1; Week 2 of treatment 2; Week 4 of treatment 4
|
Week 0; Week 2 of treatment period 1; Week 4 of treatment period 1; Week 2 of treatment 2; Week 4 of treatment 4
|
|
Change in microbiome composition
Time Frame: Week 0; Week 2 of treatment period 1; Week 4 of treatment period 1; Week 2 of treatment 2; Week 4 of treatment 4
|
Week 0; Week 2 of treatment period 1; Week 4 of treatment period 1; Week 2 of treatment 2; Week 4 of treatment 4
|
|
HDL cholesterol
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Penny M Kris-Etherton, PhD, Penn State University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PKE POTATO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
NCT07483502Not yet recruitingCardiovascular Surgery | Cardiovascular Diseases (CVD)
-
NCT07067398RecruitingCardiovascular | Cardiovascular Health | Cardiovascular (CV) Risk | Cardiovascular Disease (CVD) Risk Factors
-
NCT07497932RecruitingCardiovascular Disease | Cardiovascular Surgery
-
NCT04121741CompletedCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular Health
-
NCT03717363CompletedCardiovascular Disease | Cardiovascular Risk Factor
-
NCT06832644RecruitingCardiovascular Risk | Genetic Cardiovascular Risk
-
NCT00983333CompletedCardiovascular Disease | Cardiovascular Risk Factors
-
NCT02038101Unknown
-
NCT02777515Terminated
-
NCT07478354RecruitingCardiovascular Diseases (CVD)
Clinical Trials on Potato-based side dish
-
NCT01562171CompletedObesity | Hypercholesterolemia
-
NCT07230951RecruitingHealthy | Adult | Glycemic Response | Appetite | Mealtiming
-
NCT06626503RecruitingIdiopathic Scoliosis
-
NCT06861582RecruitingPoint-of-Care Testing | Acute Coronary Syndromes (ACS) | Troponin I
-
NCT01916213Completed
-
NCT06626035RecruitingPediatric Cardiac Surgery
-
NCT04878926CompletedTransversus Abdominis Plane (TAP) Block
-
NCT03128034RecruitingAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia
-
NCT00544115Active, not recruitingLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Precancerous/Nonmalignant Condition